Stock listing
MESO Stock Price, News, Filings & Events — Mesoblast Limited
Selected listing: MESO · NASDAQ · USD · US
This page tracks Mesoblast Limited's MESO:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following MESO:NASDAQ. MESO:NASDAQ is the stock-level entry point for investors researching Mesoblast Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- MESO:NASDAQ
- Asset type
- Stock
- Market cap
- $2.32B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Mesoblast Limited MESO:NASDAQ stock context
This page tracks Mesoblast Limited's MESO:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following MESO:NASDAQ. MESO:NASDAQ is the stock-level entry point for investors researching Mesoblast Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Mesoblast Limited
Mesoblast Reports Substantial Revenue Growth to US$120M
August 26, 2026
Major Milestone Treatment Completed in P3 Trial for CLBP
August 16, 2026
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
July 29, 2026
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
July 9, 2026
Research Mesoblast Limited
Mesoblast Limited investor report
Review AI stock analysis and investor report context for MESO:NASDAQ.
Mesoblast Limited company profile
View the public company page for Mesoblast Limited on 6ix.
Mesoblast Limited news
Read company news and market updates connected to Mesoblast Limited.
Mesoblast Limited investor events
Find investor webinars, events, and replay context for Mesoblast Limited.
Alternate listings
MSB:ASX
AU · AUD
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
LWB:GETTEX
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
MEOBF:OTC
US · USD
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
A0DNPW:LSX
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
A0DNPW:LS
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
MESO:BOATS
US · USD
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
LWB1:GETTEX
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
LWB:TRADEGATE
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
LWB:FWB
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
LWB:BX
CH · CHF
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
LWB:DUS
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.
LWB1:FWB
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is MESO:NASDAQ.